In the management of HPV-positive throat (oropharyngeal) or anal cancer
A Simple, Innovative Blood Test Is Helping Physicians Personalize HPV-Positive Cancer Care
NavDx can significantly improve your
HPV-positive cancer treatment plan
NavDx is an innovative blood test that helps physicians personalize care in HPV-positive cancers, such as head and neck (mouth or throat) or anal cancer. Routine testing with NavDx to track changes in your TTMV Score offers your physician a more complete picture of your cancer status than imaging scans alone. With a simple blood draw, NavDx can detect the presence of human papillomavirus (HPV)-positive cancer anywhere in your body, helping your physician create the best treatment plan for you.
To optimize your HPV-positive cancer care, your physician relies on NavDx to provide:
- Reliable information about your current TTMV status
- Proof of being cancer free
- Early signs of recurrence, because knowing sooner may improve your ability to fight the disease
In the management of HPV-positive cancer
Your Blood has never been more important
What is blood TTMV?
TTMV, or tumor tissue modified viral (TTMV)-HPV DNA, is a unique cancer biomarker found in people with HPV-positive cancers. Tracking your blood TTMV Score over time gives your physician valuable information about your HPV-positive cancer.
What is a biomarker?
A biomarker is a molecular characteristic of your cancer that can be measured to give your physician more information about your human papillomavirus (HPV)-positive cancer and its response to treatment.
Circulating tumor tissue modified viral (TTMV)-HPV DNA are small pieces of DNA found in the bloodstream after cancerous tumor cells die. This circulating TTMV-HPV DNA can be detected in blood samples and has become commonly used in cancer care. Circulating TTMV-HPV DNA is found in patients with HPV-driven cancers, making it an ideal biomarker.
NavDx® can monitor HPV-positive cancers in your blood during every phase of treatment
Your physician can rely on NavDx to track your TTMV® Score and personalize your care. Talk with your physician about how routine NavDx testing can help monitor your HPV-positive cancer during your entire treatment journey.
A simple blood draw will identify the exact type of HPV to help guide your treatment plan.
Establish your baseline blood TTMV Score to track any changes throughout your care.
Track changes in your TTMV Score to assess your response to treatment, detect if cancer is still in your body, and determine any next steps.
Rapid conversion from TTMV positive to TTMV negative indicates a response to treatment, and may predict control of your disease.
Regular monitoring with NavDx can help detect cancer recurrence nearly 4 months earlier than imaging, biopsies, or symptoms.
Treating a recurrence as early as possible may improve your ability to fight the disease.
Your physician may use a combination of NavDx and imaging scans to monitor for recurrence.
Even with successful initial treatment, 13%-25% of people with HPV-positive head and neck cancer have a recurrence within 5 years.
In a 3-year study, NavDx accurately and reliably predicted when cancer returned.
Among post-treatment patients:
Frequently asked questions (FAQs) regarding NavDx testing
Review our FAQs to get more information about the NavDx test and other related topics.
Experiences, materials and support for HPV-positive cancer patients and their loved ones
From shared stories of others who are using NavDx, to downloadable materials and connections to support and advocacy organizations, NavDx is committed to supporting you throughout your treatment journey.
Real Experiences with NavDx
View testimonials from others with HPV-positive oral and throat cancer and see how NavDx is helping their physicians personalize care and optimize the treatment journey.
Downloadable and Shareable Materials
These resources provide even more information about NavDx. Please download and review, or print and use.
Helpful information for patients and their loved ones, from the Centers for Disease Control and Prevention (CDC), National Comprehensive Cancer Network (NCCN), and American Cancer Society (ACS).